JP2012503621A - 生物活性プレチューブリシンおよびその使用 - Google Patents

生物活性プレチューブリシンおよびその使用 Download PDF

Info

Publication number: JP2012503621A
Authority: JP; Japan
Prior art keywords: group; pretubulin; mmol; cells; halogen
Prior art date: 2008-09-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2011528309A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012503621A5 (2

Inventor

チャイ，イ

ウルリッチ，アンジェリカ

カズマイアー，ウリ

ミュラー，ロルフ

Original Assignee

ユニベルシタートデスサーランデス

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-25

Filing date

2009-09-22

Publication date

2012-02-09

2009-09-22 Application filed by ユニベルシタートデスサーランデス filed Critical ユニベルシタートデスサーランデス

2012-02-09 Publication of JP2012503621A publication Critical patent/JP2012503621A/ja

2012-11-08 Publication of JP2012503621A5 publication Critical patent/JP2012503621A5/ja

Status Pending legal-status Critical Current

Links

230000000975 bioactive effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 30
239000003814 drug Substances 0.000 claims description 30
-1 alkylene diol Chemical class 0.000 claims description 21
229920006395 saturated elastomer Polymers 0.000 claims description 17
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 13
230000006907 apoptotic process Effects 0.000 claims description 13
229910052736 halogen Inorganic materials 0.000 claims description 13
150000002367 halogens Chemical class 0.000 claims description 13
238000000034 method Methods 0.000 claims description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 11
125000001424 substituent group Chemical group 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 9
201000011510 cancer Diseases 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 7
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
239000003080 antimitotic agent Substances 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
125000003342 alkenyl group Chemical group 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000004474 valine Substances 0.000 claims description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
125000006239 protecting group Chemical group 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
150000005846 sugar alcohols Polymers 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 2
230000001939 inductive effect Effects 0.000 claims 1
230000000144 pharmacologic effect Effects 0.000 abstract description 2
238000002360 preparation method Methods 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 98
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
102000029749 Microtubule Human genes 0.000 description 63
108091022875 Microtubule Proteins 0.000 description 63
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
210000004688 microtubule Anatomy 0.000 description 43
239000000243 solution Substances 0.000 description 36
238000005481 NMR spectroscopy Methods 0.000 description 35
230000000694 effects Effects 0.000 description 34
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
108090000704 Tubulin Proteins 0.000 description 27
102000004243 Tubulin Human genes 0.000 description 27
229940079593 drug Drugs 0.000 description 23
238000006116 polymerization reaction Methods 0.000 description 21
230000003287 optical effect Effects 0.000 description 16
239000011541 reaction mixture Substances 0.000 description 16
238000000451 chemical ionisation Methods 0.000 description 15
239000011734 sodium Substances 0.000 description 15
238000004440 column chromatography Methods 0.000 description 14
239000012074 organic phase Substances 0.000 description 13
230000016507 interphase Effects 0.000 description 12
238000000746 purification Methods 0.000 description 12
239000008346 aqueous phase Substances 0.000 description 11
239000002904 solvent Substances 0.000 description 11
238000000338 in vitro Methods 0.000 description 10
238000011534 incubation Methods 0.000 description 10
238000002844 melting Methods 0.000 description 10
230000008018 melting Effects 0.000 description 10
239000012071 phase Substances 0.000 description 10
239000007787 solid Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
238000000921 elemental analysis Methods 0.000 description 7
230000012010 growth Effects 0.000 description 7
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000022131 cell cycle Effects 0.000 description 6
238000005259 measurement Methods 0.000 description 6
230000000394 mitotic effect Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
230000001028 anti-proliverative effect Effects 0.000 description 5
230000025084 cell cycle arrest Effects 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
LADPSVVIQZPZKS-CYBMUJFWSA-N CCOC(=O)C1=CSC(CC[C@@H](NCC(=O)OC(C)(C)C)C(C)C)=N1 Chemical compound CCOC(=O)C1=CSC(CC[C@@H](NCC(=O)OC(C)(C)C)C(C)C)=N1 LADPSVVIQZPZKS-CYBMUJFWSA-N 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
239000003921 oil Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
NQYKCTXJKZUWBC-SNVBAGLBSA-N tert-butyl 2-[[(3R)-6-amino-2-methyl-6-sulfanylidenehexan-3-yl]amino]acetate Chemical compound NC(=S)CC[C@H](C(C)C)NCC(=O)OC(C)(C)C NQYKCTXJKZUWBC-SNVBAGLBSA-N 0.000 description 4
OKLDXUHSYKIPLU-VQCYPWCPSA-N tert-butyl n-[(e,3s)-1-cyano-4-methylpent-1-en-3-yl]carbamate Chemical compound N#C/C=C/[C@H](C(C)C)NC(=O)OC(C)(C)C OKLDXUHSYKIPLU-VQCYPWCPSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
GQFJNAVLHLEOAW-WCRPCQDQSA-N ethyl (e,4s)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpent-2-enoate Chemical compound CCOC(=O)C(\C)=C\[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 GQFJNAVLHLEOAW-WCRPCQDQSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000013467 fragmentation Methods 0.000 description 3
238000006062 fragmentation reaction Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
SKVPJRYXSOJCAR-HTFCCJBDSA-N methyl (2s,4r)-2-methyl-4-[[2-[(3r)-4-methyl-3-[methyl-[(2s,3r)-3-methyl-2-[methyl(piperidine-2-carbonyl)amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-5-phenylpentanoate Chemical compound CN([C@@H]([C@H](C)CC)C(=O)N(C)[C@H](CCC=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(=O)OC)CC=1C=CC=CC=1)C(C)C)C(=O)C1CCCCN1 SKVPJRYXSOJCAR-HTFCCJBDSA-N 0.000 description 3
230000029115 microtubule polymerization Effects 0.000 description 3
238000010186 staining Methods 0.000 description 3
125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
ULBDHJMIHAMJRU-ZISUOYCXSA-N C(C1=CC=CC=C1)OC(=O)N([C@@H]([C@H](C)CC)C(=O)CN[C@H](CCC=1SC=C(N=1)C(=O)O)C(C)C)C(C1NCCCC1)=O Chemical compound C(C1=CC=CC=C1)OC(=O)N([C@@H]([C@H](C)CC)C(=O)CN[C@H](CCC=1SC=C(N=1)C(=O)O)C(C)C)C(C1NCCCC1)=O ULBDHJMIHAMJRU-ZISUOYCXSA-N 0.000 description 2
AETPYOPUHGEMOK-HWHXTQLESA-N C(C1=CC=CC=C1)OC(=O)N[C@@H]([C@@H](C)CC)C(=O)CN[C@H](CCC=1SC=C(N=1)C(=O)OCC)C(C)C Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H]([C@@H](C)CC)C(=O)CN[C@H](CCC=1SC=C(N=1)C(=O)OCC)C(C)C AETPYOPUHGEMOK-HWHXTQLESA-N 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000002927 anti-mitotic effect Effects 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
239000013611 chromosomal DNA Substances 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000010908 decantation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229930187817 disorazole Natural products 0.000 description 2
230000002275 effect on microtubule Effects 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
150000002314 glycerols Chemical class 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
ORQVYLFICNWZHI-CMPLNLGQSA-N methyl (2s,4r)-4-amino-2-methyl-5-phenylpentanoate Chemical compound COC(=O)[C@@H](C)C[C@@H](N)CC1=CC=CC=C1 ORQVYLFICNWZHI-CMPLNLGQSA-N 0.000 description 2
230000025090 microtubule depolymerization Effects 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
XWMHYAQKFOPMFQ-SNVBAGLBSA-N tert-butyl n-[(3r)-1-cyano-4-methylpentan-3-yl]carbamate Chemical compound N#CCC[C@H](C(C)C)NC(=O)OC(C)(C)C XWMHYAQKFOPMFQ-SNVBAGLBSA-N 0.000 description 2
238000007817 turbidimetric assay Methods 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
RSYXORMKBUFAMS-UHFFFAOYSA-M (1-ethoxy-1-oxopropan-2-yl)-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C(C)C(=O)OCC)C1=CC=CC=C1 RSYXORMKBUFAMS-UHFFFAOYSA-M 0.000 description 1
UERNRFHISLXQFU-DFWYDOINSA-N (2S)-5-oxopyrrolidine-2-carboxylic acid pyridine Chemical compound c1ccncc1.OC(=O)[C@@H]1CCC(=O)N1 UERNRFHISLXQFU-DFWYDOINSA-N 0.000 description 1
JSHXJPFZKBRLFU-JQWIXIFHSA-N (2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 JSHXJPFZKBRLFU-JQWIXIFHSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
DWCRWWOCTYJYRV-IEZBTEQYSA-N (e,4s)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpent-2-enoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](\C=C(/C)C(O)=O)CC1=CC=CC=C1 DWCRWWOCTYJYRV-IEZBTEQYSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 description 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
241000863007 Archangium Species 0.000 description 1
241000863425 Archangium disciforme Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
UYQHSQMQMMJEQP-GXTWGEPZSA-N CC(C)(C)OC(=O)N[C@H](C[C@H](C)C(O)=O)CC1=CC=CC=C1 Chemical compound CC(C)(C)OC(=O)N[C@H](C[C@H](C)C(O)=O)CC1=CC=CC=C1 UYQHSQMQMMJEQP-GXTWGEPZSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
241000863434 Myxococcales Species 0.000 description 1
239000007990 PIPES buffer Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000008051 TBE buffer Substances 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012578 cell culture reagent Substances 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
ARPLQAMUUDIHIT-UHFFFAOYSA-M cyanomethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC#N)C1=CC=CC=C1 ARPLQAMUUDIHIT-UHFFFAOYSA-M 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229930013356 epothilone Natural products 0.000 description 1
150000003883 epothilone derivatives Chemical class 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000009878 intermolecular interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
SDSWSVBXRBXPRL-LBPRGKRZSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 SDSWSVBXRBXPRL-LBPRGKRZSA-N 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000013642 negative control Substances 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229930184737 tubulysin Natural products 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Crystallography & Structural Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

JP2011528309A 2008-09-25 2009-09-22 生物活性プレチューブリシンおよびその使用 Pending JP2012503621A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08165147.3		2008-09-25
EP08165147A EP2174947A1 (en)	2008-09-25	2008-09-25	Bioactive pre-tubulysins and use thereof
PCT/EP2009/062282 WO2010034724A1 (en)	2008-09-25	2009-09-22	Bioactive pre-tubulysins and use thereof

Publications (2)

Publication Number	Publication Date
JP2012503621A true JP2012503621A (ja)	2012-02-09
JP2012503621A5 JP2012503621A5 (2)	2012-11-08

Family

ID=39952267

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2011528309A Pending JP2012503621A (ja)	2008-09-25	2009-09-22	生物活性プレチューブリシンおよびその使用

Country Status (5)

Country	Link
US (1)	US8791098B2 (2)
EP (2)	EP2174947A1 (2)
JP (1)	JP2012503621A (2)
CA (1)	CA2738091A1 (2)
WO (1)	WO2010034724A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2018509404A (ja) *	2015-02-25	2018-04-05	ウィリアムマーシュライスユニバーシティＷｉｌｌｉａｍＭａｒｓｈＲｉｃｅＵｎｉｖｅｒｓｉｔｙ	デスアセトキシツブリシンｈおよびその類似体

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101098854B (zh)	2004-07-23	2012-12-05	恩多塞特公司	二价连接体及其轭合物
AU2008224988A1 (en)	2007-03-14	2008-09-18	Endocyte, Inc.	Binding ligand linked drug delivery conjugates of tubulysins
CN101784565B (zh)	2007-06-25	2014-12-10	恩多塞特公司	含有亲水性间隔区接头的共轭物
US9877965B2 (en)	2007-06-25	2018-01-30	Endocyte, Inc.	Vitamin receptor drug delivery conjugates for treating inflammation
US8394922B2 (en) *	2009-08-03	2013-03-12	Medarex, Inc.	Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2409983A1 (en)	2010-07-19	2012-01-25	Leibniz-Institut für Pflanzenbiochemie (IPB)	Tubulysin analogues
WO2012171020A1 (en)	2011-06-10	2012-12-13	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
US10080805B2 (en)	2012-02-24	2018-09-25	Purdue Research Foundation	Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en)	2012-03-29	2014-03-20	Endocyte, Inc.	Processes for preparing tubulysin derivatives and conjugates thereof
CN104640572B (zh)	2012-05-15	2018-04-27	索伦托医疗有限公司	药物偶联物，偶联方法，及其用途
ES2781523T3 (es)	2012-07-12	2020-09-02	Hangzhou Dac Biotech Co Ltd	Conjugados de moléculas de unión celular con agentes citotóxicos
BR112015008365A2 (pt)	2012-10-16	2017-07-04	Endocyte Inc	composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
CA2891280C (en)	2012-11-24	2018-03-20	Hangzhou Dac Biotech Co., Ltd.	Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CA2892863C (en)	2012-12-10	2022-03-15	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en)	2012-12-12	2014-06-19	Mersana Therapeutics,Inc.	Hydroxy-polmer-drug-protein conjugates
LT2956173T (lt)	2013-02-14	2017-06-26	Bristol-Myers Squibb Company	Tubulizino junginiai, gavimo ir panaudojimo būdai
WO2014160360A1 (en) *	2013-03-14	2014-10-02	Mersana Therapeutics Inc.	Tubulysin compounds and conjugates thereof
WO2015057585A1 (en) *	2013-10-14	2015-04-23	Regents Of The University Of Minnesota	Therapeutic compounds
AU2014337317A1 (en)	2013-10-15	2016-09-15	Sorrento Therapeutics Inc.	Drug-conjugates with a targeting molecule and two different drugs
NZ758049A (en)	2013-10-15	2024-03-22	Seagen Inc	Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10464955B2 (en)	2014-02-28	2019-11-05	Hangzhou Dac Biotech Co., Ltd.	Charged linkers and their uses for conjugation
US10077287B2 (en)	2014-11-10	2018-09-18	Bristol-Myers Squibb Company	Tubulysin analogs and methods of making and use
EP3250238B1 (en)	2015-01-28	2022-06-01	Sorrento Therapeutics, Inc.	Antibody drug conjugates
NZ739830A (en)	2015-07-12	2021-12-24	Hangzhou Dac Biotech Co Ltd	Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20180090290A (ko)	2015-12-04	2018-08-10	시애틀 지네틱스, 인크.	사차화 튜불리신 화합물들의 컨쥬게이트들
US11793880B2 (en)	2015-12-04	2023-10-24	Seagen Inc.	Conjugates of quaternized tubulysin compounds
CN109843919A (zh)	2016-03-25	2019-06-04	西雅图基因公司	用于制备聚乙二醇化的药物-接头及其中间体的方法
KR20220150408A (ko)	2016-11-14	2022-11-10	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
KR102648564B1 (ko)	2017-03-24	2024-03-19	씨젠 인크.	글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
WO2019108685A1 (en)	2017-11-29	2019-06-06	William March Rice University	Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
JP7590328B2 (ja)	2018-12-21	2024-11-26	レゲネロンファーマシューティカルス，インコーポレーテッド	ツブリシン及びタンパク質－ツブリシンコンジュゲート
CN114040778A (zh)	2019-06-29	2022-02-11	杭州多禧生物科技有限公司	一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法
CN111647040B (zh) *	2020-05-11	2022-02-22	深圳市老年医学研究所	一种天然活性多肽Tubulysin U的制备方法
EP4426727A2 (en)	2021-11-03	2024-09-11	Hangzhou Dac Biotech Co., Ltd.	Specific conjugation of an antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006518704A (ja) *	2002-11-21	2006-08-17	ゲゼルシャフトフュアバイオテクノロギッシェフォーシュングエムベーハー（ゲーベーエフ）	チューブライシン、その製造方法、及び、チューブライシン製剤
WO2008106080A2 (en) *	2007-02-27	2008-09-04	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Synthesis of desacetoxytubulysin h and analogs thereof

2008
- 2008-09-25 EP EP08165147A patent/EP2174947A1/en not_active Withdrawn
2009
- 2009-09-22 EP EP09783296A patent/EP2331559A1/en not_active Withdrawn
- 2009-09-22 JP JP2011528309A patent/JP2012503621A/ja active Pending
- 2009-09-22 WO PCT/EP2009/062282 patent/WO2010034724A1/en not_active Ceased
- 2009-09-22 US US13/120,497 patent/US8791098B2/en not_active Expired - Fee Related
- 2009-09-22 CA CA2738091A patent/CA2738091A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006518704A (ja) *	2002-11-21	2006-08-17	ゲゼルシャフトフュアバイオテクノロギッシェフォーシュングエムベーハー（ゲーベーエフ）	チューブライシン、その製造方法、及び、チューブライシン製剤
WO2008106080A2 (en) *	2007-02-27	2008-09-04	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Synthesis of desacetoxytubulysin h and analogs thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014012125; Ｂｉｏｏｒｇ　Ｍｅｄ　Ｃｈｅｍ　Ｌｅｔｔ．Ｖｏｌ．１８，　Ｎｏ，９, 20080320, ｐ．２９９６-２９９９ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2018509404A (ja) *	2015-02-25	2018-04-05	ウィリアムマーシュライスユニバーシティＷｉｌｌｉａｍＭａｒｓｈＲｉｃｅＵｎｉｖｅｒｓｉｔｙ	デスアセトキシツブリシンｈおよびその類似体

Also Published As

Publication number	Publication date
CA2738091A1 (en)	2010-04-01
US8791098B2 (en)	2014-07-29
EP2174947A1 (en)	2010-04-14
EP2331559A1 (en)	2011-06-15
WO2010034724A1 (en)	2010-04-01
US20110245295A1 (en)	2011-10-06

Legal Events

Date	Code	Title	Description
2012-09-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120921
2012-09-22	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120921
2014-03-26	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140325
2014-06-25	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140624
2014-07-02	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140701
2014-09-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140925
2015-03-04	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150303

Publication	Publication Date	Title
JP2012503621A (ja)	2012-02-09	生物活性プレチューブリシンおよびその使用
CA2937731C (en)	2019-09-24	Bifunctional cytotoxic agents
AU2022287001A1 (en)	2023-10-26	Antibody drug conjugate, and preparation method therefor and use thereof
FI115056B (fi)	2005-02-28	Uusia välituotteena käytettäviä oksatsoliinisivuketjullisia taksaaneja ja menetelmä niiden valmistamiseksi
US6825166B2 (en)	2004-11-30	Molecular conjugates for use in treatment of cancer
CN108299458B (zh)	2020-10-02	冬凌草甲素衍生物及其制备方法和应用
AU2002254400A1 (en)	2003-03-27	Molecular conjugates for use in treatment of cancer
JPWO1993003054A1 (ja)	1993-08-05	新規なテトラペプチド誘導体
LT3626B (en)	1995-12-27	Compounds containing a fused bicycle ring and processing thereof
CN119630672B (zh)	2026-01-30	喜树碱衍生物及其偶联物以及其制备方法和医药用途
WO1998002426A1 (en)	1998-01-22	Taxane derivatives and drugs containing the same
JP2018535255A (ja)	2018-11-29	新規なクリプトフィシン化合物およびコンジュゲート、これらの製造およびこれらの治療用途
JP7377242B2 (ja)	2023-11-09	ヒストンデアセチラーゼの阻害剤としての大環状分子のチオエステルプロドラッグ
AU758418B2 (en)	2003-03-20	Taxane derivatives
KR20060129069A (ko)	2006-12-14	카스파제 억제제 및 이의 용도
Sazanova et al.	2020	Allocolchicinoids bearing a Michael acceptor fragment for possible irreversible binding of tubulin
US5589502A (en)	1996-12-31	Baccatin derivatives and processes for preparing the same
CN115335081B (zh)	2026-05-01	靶向血浆蛋白降解
CN121293273A (zh)	2026-01-09	一种抗体偶联药物毒素mmae的合成方法
KR100505779B1 (ko)	2005-08-04	제약 화합물
HK40031377A (en)	2021-03-12	Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
HK1204273B (en)	2018-05-04	Cytotoxic peptides and antibody drug conjugates thereof
WO2002034283A2 (en)	2002-05-02	Vegh inhibitors and their use
HK1228891A1 (en)	2017-11-10	Epoxyketone compounds for enzyme inhibition
HK1159614B (en)	2013-11-22	Caspase inhibitors and uses thereof

JP2012503621A - 生物活性プレチューブリシンおよびその使用 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (2)

Family

ID=39952267

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (35)

Citations (2)

Patent Citations (2)

Non-Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events